New insights into molecular mechanisms of sunitinib-associated side effects
Ver/ abrir
Use este enlace para citar
http://hdl.handle.net/2183/20418Coleccións
- INIBIC-OCT - Artigos [21]
Metadatos
Mostrar o rexistro completo do ítemTítulo
New insights into molecular mechanisms of sunitinib-associated side effectsAutor(es)
Data
2011-12Cita bibliográfica
Aparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther. 2011; 10(12):2215-23
Resumo
[Abstract] The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated adverse events.
Palabras chave
Antineoplastic agents
Carcinoma, Renal cell
Hypertension
Hypothyroidism
Indoles
Kidney neoplasms
Pigmentation disorders
Pyrroles
Signal transduction
Carcinoma, Renal cell
Hypertension
Hypothyroidism
Indoles
Kidney neoplasms
Pigmentation disorders
Pyrroles
Signal transduction
Descrición
Review
Versión do editor
ISSN
1535-7163
1538-8514
1538-8514